A Phase I, Multi-center, Open Label, Dose Escalation Study of LEQ506, an Oral Smoothened Inhibitor, in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2015
At a glance
- Drugs LEQ 506 (Primary)
- Indications Basal cell cancer; Medulloblastoma; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis
- 09 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 27 May 2014 Planned End Date changed from 1 Jan 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
- 13 May 2013 Planned end date changed from 1 Jul 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.